Bisdemethoxycurcumin

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Model organisms1

Outcomes

Locomotion

upin worms1

1 study

Bisdemethoxycurcumin improves locomotion in worms.
“BDMC also improved healthspan-associated phenotypes, including locomotion and fertility”
Model organisms
Bisdemethoxycurcumin extends lifespan and healthspan in Caenorhabditis elegans via modulation of EGFR-linked signaling pathways
Food & function10 Mar 2026

Senescence-associated beta-galactosidase

downin worms1

1 study

Bisdemethoxycurcumin decreases senescence-associated beta-galactosidase in worms.
“reducing senescence-associated β-galactosidase activity and lipid accumulation”
Model organisms
Bisdemethoxycurcumin extends lifespan and healthspan in Caenorhabditis elegans via modulation of EGFR-linked signaling pathways
Food & function10 Mar 2026

More on Senescence-associated beta-galactosidase

Lifespan

upin worms1+18% mean lifespan

1 study

Bisdemethoxycurcumin extends lifespan in worms (+17.7% mean lifespan).
“Continuous BDMC treatment initiated at the L4 stage significantly extended mean lifespan by 17.7%”
Model organisms100 μM
Bisdemethoxycurcumin extends lifespan and healthspan in Caenorhabditis elegans via modulation of EGFR-linked signaling pathways
Food & function10 Mar 2026

Latest

1 in 12 months

Food & Function10 Mar